. 2020 May 4;123(1):155–160. doi: 10.1038/s41416-020-0850-6

Table 1.

Detection rate, PPV of cytology and RRs for CIN2+, in relation to age at vaccination initiation.

Cytological results	Age at vaccination initiation	Screened	Screen positive	CIN2+	Detection rate of CIN2+, % (95% CI)^a	PPV
Cytological results	Age at vaccination initiation	n	n	n	Detection rate of CIN2+, % (95% CI)^a	PPV for CIN2+, % (95% CI)^b	Crude RR (95% CI)	Adjusted^c RR (95% CI)
High-grade cytology
	Unvaccinated	100,400	2110	1475	1.5 (1.4–1.5)	69.9 (67.9–71.9)	Reference	Reference
	Vaccinated at age 17–22 years	26,892	368	239	0.9 (0.8–1.0)	64.9 (59.8–69.8)	0.93 (0.86–1.01)	0.92 (0.85–1.00)
	Vaccinated at age <17 years	25,865	244	140	0.5 (0.5–0.6)	57.4 (50.9–63.7)	0.82 (0.73–0.92)	0.83 (0.74–0.93)
Low-grade cytology
	Unvaccinated	100,400	12,293	2325	2.3 (2.2–2.4)	18.9 (18.2–19.6)	Reference	Reference
	Vaccinated at age 17–22 years	26,892	2940	377	1.4 (1.3–1.5)	12.8 (11.6–14.1)	0.68 (0.61–0.75)	0.72 (0.65–0.80)
	Vaccinated at age <17 years	25,865	2775	258	1.0 (0.9–1.0)	9.3 (8.2–10.4)	0.49 (0.44–0.56)	0.56 (0.49–0.63)

PPV positive predictive value, RR risk ratio, CIN2+ cervical intraepithelial neoplasia grade 2 or worse.

^aDetection rate = no. of women confirmed as CIN2+/no. of women screened × 100%.

^bPPV = no. of women confirmed as CIN2+/no. of women screen positive × 100%.

^cAdjusted for birth cohort.